PEDIATRIC ONCOLOGY GROUP--THE CAROLINAS CONSORTIUM

描述(根据申请者的描述改编)：院校 包括在这项提案中的是儿科肿瘤学小组的一部分 (POG)，并在过去五年中获得了良好的表现分数。 这项拟议的研究有两个主要目标；第一个是 让患者参加团体临床试验，以确定 为患有各种癌症的儿童提供最佳护理。第二个是 在两个病人护理领域为集团贡献科学专业知识 和肿瘤生物学。这项拟议的研究将允许参与POG 通过东卡罗来纳大学(ECU)财团的努力开展的活动 南方医科大学卡罗莱纳医学中心医学院 卡罗莱纳(MUSC)、格林维尔医院、长老会医院和纪念馆 教会医院(卡罗莱纳州联盟)。除了这些临床应用之外 未来五年，他们的科学努力将包括：(1) 开发治疗儿童癌症的新方案 主要集中于儿童淋巴瘤；(2)扩大对儿童淋巴瘤的研究 骨髓残留病(使用RT-PCR分析)和新的评估 神经母细胞瘤的净化技术；(3)参与实验室 新生鼠淋巴母细胞叶基多谷氨酸合成酶的检测 确诊的患者；以及(4)对造血生长的作用的评估 影响儿童恶性肿瘤治疗的因素。

DESCRIPTION (Adapted from the applicant's description): The institutions included in this proposal have been part of the Pediatric Oncology Group (POG) and received good performance scores during the past five years. There are two primary goals of this proposed research; the first is to accrue patients to the Group clinical trials in order to determine the optimal care of children with all types of cancers. The second is to contribute scientific expertise to the Group in areas of both patient care and tumor biology. This proposed research will allow participation in POG activities through a consortium effort of East Carolina University (ECU) School of Medicine, Carolinas Medical Center, Medical University of South Carolina (MUSC), Greenville Hospital, Presbyterian Hospital, and Memorial Mission Hospital (The Carolinas' Consortium). In addition to these clinical activities, their scientific efforts in next five years will include: (1) development of new protocols for the treatment of children with cancer focusing mainly on pediatric lymphomas; (2) expansion of studies of minimal marrow residual disease (using RT-PCR analysis) and assessment of new purging techniques in neuroblastoma; (3) participation in the laboratory evaluation of folylpolyglutamate synthetase (FPGS) in lymphoblasts of newly diagnosed patients; and (4) evaluation of the role hematopoietic growth factors in the treatment of pediatric malignancies.